Moomoo AI 已提取核心訊息
ARK Investment Management LLC, an investment adviser based in Delaware, United States, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on January 10, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing, which reflects the state of ownership as of December 31, 2023, shows that ARK Investment Management LLC has beneficial ownership of 8,536,104 shares of CRISPR Therapeutics' common stock, representing 10.75% of the class. The investment firm has sole voting power over 8,057,147 shares and shared voting power over 244,377 shares. Additionally, ARK Investment Management LLC possesses sole dispositive power over the entire 8,536,104 shares it owns. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
ARK Investment Management LLC, an investment adviser based in Delaware, United States, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on January 10, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing, which reflects the state of ownership as of December 31, 2023, shows that ARK Investment Management LLC has beneficial ownership of 8,536,104 shares of CRISPR Therapeutics' common stock, representing 10.75% of the class. The investment firm has sole voting power over 8,057,147 shares and shared voting power over 244,377 shares. Additionally, ARK Investment Management LLC possesses sole dispositive power over the entire 8,536,104 shares it owns. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
總部位於美國特拉華州的投資顧問方舟投資管理有限責任公司已於2024年1月10日向美國證券交易委員會提交了經修訂的附表13G，表明CRISPR Therapeutics AG擁有大量所有權。該文件反映了截至2023年12月31日的所有權狀況，顯示方舟投資管理有限責任公司擁有CRISPR Therapeutics普通股8,536,104股的實益所有權，佔該類別的10.75％。該投資公司擁有超過8,057,147股股票的唯一投票權，共享投票權超過244,377股。此外，ARK投資管理有限責任公司對其擁有的全部8,536,104股股票擁有唯一的處置權。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。
總部位於美國特拉華州的投資顧問方舟投資管理有限責任公司已於2024年1月10日向美國證券交易委員會提交了經修訂的附表13G，表明CRISPR Therapeutics AG擁有大量所有權。該文件反映了截至2023年12月31日的所有權狀況，顯示方舟投資管理有限責任公司擁有CRISPR Therapeutics普通股8,536,104股的實益所有權，佔該類別的10.75％。該投資公司擁有超過8,057,147股股票的唯一投票權，共享投票權超過244,377股。此外，ARK投資管理有限責任公司對其擁有的全部8,536,104股股票擁有唯一的處置權。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。
有用
沒用